• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Choice of Antiplatelet Dual Combination in Coronary Artery Disease: Is this Just a Question of Balance between ischemic Burden and Bleeding Risk?

作者信息

Almeida Maria Cristina, Castro Marildes Luiza de, Espíndola Larissa Neto

机构信息

Centro Universitário de Belo Horizonte, Belo Horizonte, MG - Brasil.

Universidade Federal de Minas Gerais - Faculdade de Medicina, Belo Horizonte, MG - Brasil.

出版信息

Arq Bras Cardiol. 2025 Jan 20;121(11):e20240695. doi: 10.36660/abc.20240695. eCollection 2025.

DOI:10.36660/abc.20240695
PMID:39841773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11809845/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68fe/11809845/1fb806edf73f/0066-782X-abc-121-11-e20240695-gf02-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68fe/11809845/898628d2590b/0066-782X-abc-121-11-e20240695-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68fe/11809845/0cc35b0fc1eb/0066-782X-abc-121-11-e20240695-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68fe/11809845/3cc1cf2daad4/0066-782X-abc-121-11-e20240695-gf01-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68fe/11809845/1fb806edf73f/0066-782X-abc-121-11-e20240695-gf02-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68fe/11809845/898628d2590b/0066-782X-abc-121-11-e20240695-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68fe/11809845/0cc35b0fc1eb/0066-782X-abc-121-11-e20240695-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68fe/11809845/3cc1cf2daad4/0066-782X-abc-121-11-e20240695-gf01-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68fe/11809845/1fb806edf73f/0066-782X-abc-121-11-e20240695-gf02-en.jpg

相似文献

1
The Choice of Antiplatelet Dual Combination in Coronary Artery Disease: Is this Just a Question of Balance between ischemic Burden and Bleeding Risk?冠状动脉疾病中抗血小板双联组合的选择：这仅仅是缺血负担与出血风险之间平衡的问题吗？
Arq Bras Cardiol. 2025 Jan 20;121(11):e20240695. doi: 10.36660/abc.20240695. eCollection 2025.
2
Tailoring antiplatelet therapy in older patients with coronary artery disease.为老年冠心病患者定制抗血小板治疗方案。
Platelets. 2023 Dec;34(1):2285446. doi: 10.1080/09537104.2023.2285446. Epub 2023 Dec 5.
3
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.外周动脉疾病患者冠状动脉支架置入术后延长双联抗血小板治疗：双联抗血小板治疗研究的亚分析。
JACC Cardiovasc Interv. 2017 May 8;10(9):942-954. doi: 10.1016/j.jcin.2017.02.013.
4
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.需要紧急冠状动脉旁路移植手术的患者的双联抗血小板治疗：加拿大心血管学会的立场声明。
Can J Cardiol. 2009 Dec;25(12):683-9. doi: 10.1016/s0828-282x(09)70527-6.
5
Is There an Optimal Antiplatelet Strategy after Gastrointestinal Bleeding in Patients with Coronary Artery Disease?
Cardiology. 2021;146(6):668-677. doi: 10.1159/000517051. Epub 2021 Sep 14.
6
Dual Antiplatelet Therapy: A Concise Review for Clinicians.双联抗血小板治疗：给临床医生的简明综述
Life (Basel). 2023 Jul 18;13(7):1580. doi: 10.3390/life13071580.
7
Indian Perspective on De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy Study: A Knowledge, Attitude, and Practice Study among Indian Interventional Cardiologists.印度关于双联抗血小板治疗向单联抗血小板治疗降级的观点：印度介入心脏病学家的知识、态度和实践研究。
J Assoc Physicians India. 2024 Apr;72(4):68-78. doi: 10.59556/japi.72.0515.
8
Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study.利伐沙班用于下肢外周动脉疾病血运重建术后有症状患者的双抗血栓和抗血小板治疗比较：一项回顾性队列研究
Ther Adv Chronic Dis. 2023 Dec 6;14:20406223231213262. doi: 10.1177/20406223231213262. eCollection 2023.
9
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.接受冠状动脉介入治疗后接受双联抗血小板治疗和三联治疗的患者的出血风险：ADAPTT 回顾性基于人群的队列研究。
Health Technol Assess. 2023 May;27(8):1-257. doi: 10.3310/MNJY9014.
10
Effect of dual antiplatelet therapy prolongation in acute coronary syndrome patients with both high ischemic and bleeding risk: insight from the OPT-CAD study.延长双联抗血小板治疗对急性冠状动脉综合征中缺血和出血风险均高的患者的影响：来自OPT-CAD研究的见解
Front Cardiovasc Med. 2023 Sep 8;10:1201091. doi: 10.3389/fcvm.2023.1201091. eCollection 2023.

本文引用的文献

1
Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR.土耳其人群中的冠心病患者固定剂量抗血小板双联治疗：DAPT-TR。
Arq Bras Cardiol. 2024 Oct;121(11):e20240202. doi: 10.36660/abc.20240202.
2
Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions.高出血风险的抗血栓治疗，第 I 部分：经皮心脏介入治疗。
JACC Cardiovasc Interv. 2024 Oct 14;17(19):2197-2215. doi: 10.1016/j.jcin.2024.08.022.
3
2024 ESC Guidelines for the management of chronic coronary syndromes.
2024年欧洲心脏病学会慢性冠状动脉综合征管理指南
Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177.
4
The key role of thrombosis: focus on acute coronary syndrome, venous thrombo-embolism, and atrial fibrillation.血栓形成的关键作用：聚焦于急性冠状动脉综合征、静脉血栓栓塞症和心房颤动。
Eur Heart J. 2024 Jan 1;45(1):1-4. doi: 10.1093/eurheartj/ehad835.
5
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.经皮冠状动脉介入治疗和药物洗脱支架置入术后双联抗血小板治疗：系统评价和网络荟萃分析。
Circulation. 2020 Oct 13;142(15):1425-1436. doi: 10.1161/CIRCULATIONAHA.120.046308. Epub 2020 Aug 3.
6
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.定义经皮冠状动脉介入治疗患者的高出血风险：来自高出血风险学术研究联合会的共识文件。
Eur Heart J. 2019 Aug 14;40(31):2632-2653. doi: 10.1093/eurheartj/ehz372.
7
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.双联抗血小板治疗的持续时间基于冠状动脉支架置入术后的缺血和出血风险。
J Am Coll Cardiol. 2019 Feb 26;73(7):741-754. doi: 10.1016/j.jacc.2018.11.048.
8
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).2017年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的冠状动脉疾病双联抗血小板治疗重点更新：欧洲心脏病学会（ESC）和欧洲心胸外科学会（EACTS）冠状动脉疾病双联抗血小板治疗特别工作组。
Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.